Hospital managers' need for information in decision-making:An interview study in nine European countries by Kidholm, Kristian et al.
Syddansk Universitet
Hospital managers' need for information in decision-making
Kidholm, Kristian ; Ølholm, Anne Mette; Birk-Olsen, Mette; Cicchetti, Americo; Fure, Brynjar;
Halmesmäki, Esa; Kahveci, Rabia; Kiivet, Raul Allan; Wasserfallen, Jean Blaise; Wild,
Claudia; Sampietro-Colom, Laura
Published in:
Health Policy
DOI:
10.1016/j.healthpol.2015.08.011
Publication date:
2015
Document version
Final published version
Document license
CC BY-NC-ND
Citation for pulished version (APA):
Kidholm, K., Ølholm, A. M., Birk-Olsen, M., Cicchetti, A., Fure, B., Halmesmäki, E., ... Sampietro-Colom, L.
(2015). Hospital managers' need for information in decision-making: An interview study in nine European
countries. Health Policy, 119(11), 1424-1432. DOI: 10.1016/j.healthpol.2015.08.011
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 19. Apr. 2017
Health Policy 119 (2015) 1424–1432
Contents lists available at ScienceDirect
Health  Policy
j ourna l ho me  pa g e: www.elsev ier .com/ locate /hea l thpol
Hospital  managers’  need  for  information  in  decision-making
–  An  interview  study  in  nine  European  countries
Kristian  Kidholma,∗,  Anne  Mette  Ølholma,  Mette  Birk-Olsena,
Americo  Cicchettib,  Brynjar  Furec,  Esa  Halmesmäkid, Rabia  Kahvecie,
Raul-Allan  Kiivet f,  Jean-Blaise  Wasserfalleng, Claudia  Wildh,
Laura  Sampietro-Colomi
a Odense University Hospital, Department for Quality, Research and Health Technology Assessment, Sdr. Boulevard 29, 5000 Odense C,
Denmark
b Catholic University of the Sacred Heart, Department of Economics and Management and ALTEMS (Graduate School of Health
Economics and Management), Largo F. Vito 1, 00168 Rome, Italy
c The National Knowledge Center for the Health Services, P.O. Box 7004 St Olavs plass, N-0130 Oslo, Norway
d Helsinki and Uusimaa Hospital District, P.O. Box 705, 00029 Hus, Finland
e Ankara Numune Training and Research Hospital, HTA Unit (ANHTA), Ulku Mahallesi Talatpasa Bulvari No. 5, Altindag, 06100 Ankara,
Turkey
f Medical Direction, Tartu University Clinics, L.Puusepp st 1a, Tartu 50406, Estonia
g Medical Direction, Lausanne University Hospital (CHUV), Bugnon 21, Lausanne VD CH-1011, Switzerland
h Ludwig Boltzmann Institute für Health Technology Assessment, Garnisongasse 7/20, 1090 Wien/Vienna, Austria
i Evaluation of Innovation and New Technologies, Hospital Clínic Barcelona, C/ Villarroel 170, 1.7., 08036 Barcelona, Spain
a  r  t  i c  l  e  i  n  f  o
Article history:
Received 13 March 2015
Received in revised form 13 August 2015
Accepted 17 August 2015
Keywords:
HTA
Hospital based HTA
Decision making
Informational needs
Decision makers
a  b  s  t  r  a  c  t
Assessments  of  new  health  technologies  in  Europe  are  often  made  at the  hospital  level.
However,  the  guidelines  for  health  technology  assessment  (HTA),  e.g.  the  EUnetHTA  Core
Model,  are  produced  by  national  HTA  organizations  and  focus  on decision-making  at the
national  level.  This paper  describes  the  results  of an  interview  study  with  European  hos-
pital managers  about  their need  for information  when  deciding  about  investments  in  new
treatments.  The  study  is  part  of  the  AdHopHTA  project.  Face-to-face,  structured  interviews
were conducted  with  53  hospital  managers  from  nine  European  countries.  The hospital
managers  identiﬁed  the  clinical,  economic,  safety  and  organizational  aspects  of  new  treat-
ments as being  the  most  relevant  for  decision-making.  With  regard  to  economic  aspects,  the
hospital  managers  typically  had  a  narrower  focus  on budget  impact  and  reimbursement.
In  addition  to the  information  included  in traditional  HTAs,  hospital  managers  sometimes
needed  information  on  the political  and  strategic  aspects  of  new  treatments,  in  particular
the  relationship  between  the treatment  and  the  strategic  goals  of the  hospital.  If further
studies  are  able  to verify  our  results,  guidelines  for hospital-based  HTA  should  be  altered
to reﬂect  the  information  needs  of  hospital  managers  when  deciding  about  investments  in
new  treatments.
© 2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under
the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
In many countries new health technologies (e.g. new
pharmaceuticals or new devices) are being systematically
assessed by national or regional health authorities before
decisions on investment and implementation are made
at the local hospitals [1]. However, the number of new
health technologies considered and implemented at hospi-
tals each year is often much higher than the capacity of the
national Health Technology Assessment (HTA) units [2–4].
Hospitals have therefore started producing their own  hos-
pital based HTAs. Examples can be found from e.g. Canada,
Spain, Italy, Denmark, Norway, France, Israel, Australia and
USA [5–13].
Several guidelines exist on how to produce HTA and
what type of information they should include. An exam-
ple is the EUnetHTA HTA Core Model [14,15] that describes
outcome measures divided into nine domains. This model
was developed by a large number of primarily national HTA
institutions. Little is known, however, about the compli-
ance between this and other HTA models and the need for
information on new health technologies by administrative
and clinical hospital managers.
This subject is being studied in the European FP7
research project AdHopHTA [16]. The overall objective of
this project is to strengthen the use and impact of HTA
in hospitals. AdHopHTA brings together 10 partners from
nine different countries: six hospitals with HTA programs
(Spain, Denmark, Finland, Switzerland, Italy, Turkey); one
hospital without a HTA program (Estonia); two national
HTA agencies (Norway and Austria); and one business
school (Spain).
The overall aim of this study is to understand which
information European hospital managers need when mak-
ing decision on investment in new health technologies.
The results of the study should also form the basis for the
development of guidelines for hospital based HTA in the
AdHopHTA project.
A systematic literature review was carried out before
starting this study [17]. The aim of the review was  to iden-
tify empirical studies on the information hospital managers
need when deciding on health technology investments.
The review included 14 empirical studies. The studies
were mainly semi-structured interviews and question-
naire surveys with health care managers from Europe,
USA and Australia. The main results found were, that
hospital managers most frequently mentioned the clini-
cal effectiveness and the economic aspects as the most
important aspects of new technologies in decision mak-
ing. In parallel to this, an interview study [18] shows
that hospital managers ranked information about clinical
effectiveness and economic impact as most important in
decision making. Secondly, that hospital managers rarely
mentioned information on the ethical, legal and social
aspects of new technologies as being important. Thirdly,
that even though the political and strategic aspects of
technology investments are traditionally not part of a
HTA, the hospital managers often considered these aspects
as important when making investment decisions. As an
example a Canadian study [19] reported that hospital man-
agers also included considerations regarding prestige and
competition among hospitals in their decision making.
Finally, the review shows that hospital managers needed
information on the economic aspects including on the one
hand societal cost-effectiveness analysis and on the other
hand more narrow hospital budget impact analysis.
In the light of the results of the systematic literature
review it was  decided that the interview study should
speciﬁcally examine (i) whether information on some
aspects of new health technologies are considered more
important than other aspects, (ii) whether the political or
strategic aspects of investment in new technologies should
be included in hospital based HTA and (iii) whether infor-
mation on the economic aspects of investment in new
technologies should include description of the societal
cost-effectiveness or the budget impact for the hospital or
both.
2. Materials and methods
The study involved face-to-face, structured interviews
with convenience samples of hospital managers in nine
European countries.
2.1. The interview guide
An interview guide was  developed including seven
background questions dealing with the hospital and the
respondent (e.g. size and type of hospital and the gender,
age and education of the respondent), three introduc-
tory questions regarding decision making at the hospital
in general, ﬁve questions about the information needed
for decision-making and six questions about the decision-
making process. See the interview guide in the online
Appendix. The current article presents the answers to the
questions about hospital managers’ informational needs.
The interview guide also included information about
the nine domains of the HTA Core Model as well as the
domain covering strategic and political aspects identiﬁed
in the literature [18,19]. In an attempt to avoid biasing
the respondents in favor of HTA, the questionnaire did not
include questions about the respondents’ perception of the
value of the content of HTA. Instead, an open question was
asked at the beginning of the interview (see Question 4 in
Box 1).
The interviewer noted all the information mentioned
by the respondents in answer to the ﬁrst question (see
Question 4 in Box 1) using the respondents own  wording.
If a respondent did not spontaneously mention infor-
mational needs within one or more of the 10 domains, the
interviewer then asked explicitly about that domain (see
Question 5 in Box 1).
The respondents’ full answer to the question including
explanations and examples were recorded or noted by the
interviewer.
Finally, respondents were asked (in Question 6, see Box
1) to assess whether information on some domains were
more or less relevant from their point of view. The objective
of this question was to test, whether some types of infor-
mation was  in fact more important to hospital managers
than others as the literature review indicated [17].
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Box 1: Questions about decision makers need
for information.
Question 4:
Which information would you – in the ideal situation –
wish to have at your disposal as a basis for your deci-
sion on whether or not to invest in a new treatment?
Question 5: (Ask only if the following domains have
not been touched upon)
Do you think that the following should be part of the
basis for decision making:
a. Information on the health problem of the patients,
the patients’ needs and the current technology
should be part of the basis for decision making?
b. Information on the characteristics and content of the
new treatment should be part of the basis for deci-
sion making?
c. Information on the clinical effectiveness of and
patient satisfaction with the new treatment should
be part of the basis for decision making?
d. Information on safety aspects of the new treatment
should be part of the basis for decision making?
e. Information on the economic aspects of the new
treatment should be part of the basis for decision
making?
f. Information on the ethical aspects of the new treat-
ment should be part of the basis for decision
making?
g. Information on the internal and external organiza-
tional aspects of the new treatment should be part
of the basis for decision making?
h. Information on the social aspects, e.g. inﬂuence on
the life of the patients, of the new treatment should
be part of the basis for decision making?
i. Information on the legal aspects of the new treat-
ment should be part of the basis for decision
making?
j. Information on political and strategic aspects of the
new treatment?
Question 6:
We have now been through a number of different infor-
mation or criteria that according to you should be
part of a basis for decision making. Could you assess
whether some of this information is “highly relevant”
and other “less relevant”?
If “yes” → Please indicate the most relevant informa-
tion?
An interview instruction was produced to assist the
interviewers in this task (see online Appendix). To sim-
plify the analysis of the answers, each partner was  asked
to report the results in a Reporting template in English (see
online Appendix).
Thus, the interviewers should summarize each respon-
dents’ answer to each of the questions in the questionnaire
without limitation on lengths of the text etc. The inter-
viewers were also asked to record expressive quotations
from the respondents in order to document and support
the ﬁndings.
To avoid misunderstandings and -interpretations the
interviewers were also asked to resubmit the template
with the answers from the interview to the respondent for
approval.
The interview guide was piloted with three man-
agers at Odense University Hospital (Denmark) to check
its construct validity. The questions were generally well
understood by the respondents. However, the respondents
stated that the term “new health technologies” were con-
sidered to be a very broad term that made it difﬁcult
to answer the questions. One respondent mentioned that
his need for information varied depending on the type of
health technology in question. Therefore it was decided to
use the term “treatment” in order to focus on the smaller
group of new medical or surgical treatments with a clear
clinical objective.
2.2. The respondents
Respondents were clinical managers (i.e. head of clinical
departments) and hospital managers (i.e. chief executive
ofﬁcer or chief medical ofﬁcer) of hospitals in the nine
countries participating in the AdHopHTA project.
The respondents were a convenience sample since
partners from each country were asked to select the
respondents. Partners were asked to interview one clini-
cal manager and one hospital manager from three different
types of hospitals:
• A university hospital/research and training hospital with
a HTA unit.
• A  university hospital/research and training hospital with-
out a HTA unit.
• A small/middle size hospital.
The total sample was  thus expected to consist of six
managers from each country, with 54 respondents in total.
Each respondent was  contacted by email by the local
partners. Hereafter, the place and time for the meeting was
arranged with each respondent. Usually the interview took
place at the hospital where the hospital manager or clin-
ical manager was  working. Interviews were conducted by
the study partners in the local language. Generally, two
interviewers participated in each interview.
2.3. Data analysis
Analysis of data from the interviews was  done by use of
content analysis [20] by the Danish partners in the project.
Firstly the team of Danish partners (KK, AMØ, MBO) read
the reporting templates to get a ﬁrst overall picture of the
data. Hereafter, answers to the questions about informa-
tion needs (see Questions 4–6 in Box 1) were coded to
identify the terms and concepts used in the description of
the need for information on new treatments within each of
the nine domains in the HTA Core Model and the additional
domain on political and strategic aspects.
Coding was done for the existence of a concept within
the answers to each of the three questions (see Box 1) and
not for the frequency of the use of the concept by each
respondent. The terms and concepts were hereafter exam-
ined using conceptual analysis to establish the existence
and frequency of concepts within the 10 domains. This was
done manually without the use of a software program.
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Table  1
Description of respondents by country, managerial position, age, gender and education.
Country Number of
respondents
Proportion of
hospital
managers
Proportion of
managers from
university hospitals
Mean age
(years)
Proportion of
women
Proportion
with a medical
education
Austria 7 3/7 4/7 52.7 1/7 6/7
Denmark 6 3/6 4/6 53.6 1/6 6/6
Spain  6 3/6 4/6 55.8 3/6 6/6
Estonia 6 3/6 4/6 55.3 1/6 5/6
Finland 6 3/6 4/6 54.4 1/6 6/6
Italy  6 3/6 4/6 62.8 0/6 6/6
Norway 4 2/4 3/4 52.8 1/4 3/4
Switzerland 6 4/6 4/6 60.0 0/6 5/6
Turkey 6 4/6 4/6 46.5 0/6 6/6
Total  53 52.8% 66.0% 54.9 15.1% 92.4%
Table 2
Types of information that hospital and clinical managers wish to have at their disposal as a basis for decision making (based on Questions 4 and 5).
Answers to Question 4 Answers to Question 5 Answers in total
Number of
respondents
(% total) Number of
respondents
(% total) Number of
respondents
(% total)
D1: Health problem 27 (50.9%) 15 (28.3%) 42 (79.2%)
D2:  Content of treatment 16 (30.2%) 15 (28.3%) 31 (58.5%)
D3:  Clinical effectiveness 41 (77.4%) 7 (13.2%) 48 (90.6%)
D4:  Safety 23 (43.4%) 22 (41.5%) 45 (84.9%)
D5:  Economics 50 (94.3%) 3 (5.7%) 53 (100.0%)
D6:  Ethics 6 (11.3%) 34 (64.2%) 40 (75.5%)
D7:  Organizational aspects 23 (43.4%) 28 (52.8%) 51 (96.2%)
D8:  Social aspects 4 (7.5%) 33 (62.3%) 37 (69.8%)
D9:  Legal aspects 3 (5.7%) 38 (71.7%) 41 (77.4%)
D10:  Political and strategic aspects 11 (20.8%) 32 (60.4%) 43 (81.1%)
3. Results
3.1. The respondents
The interviews were conducted in April–June 2013. Fifty
of the interviews were carried out as personal interview,
and three were done by telephone for practical reasons.
The mean duration of the interviews was 40 min.
Table 1 displays the characteristics of the respondents.
About 50% are hospital managers (the rest being clini-
cal managers) and 66% are from university hospitals as
planned. Most of the respondents were male medical doc-
tors aged 50–60.
3.2. Managers need for information on new treatments
All of the respondents were able to answer the ques-
tion on the type of information they in the ideal situation
wish to have as the basis for making decisions on new
treatments (see Question 4 in Box 1). The information
most frequently mentioned was about economics, clini-
cal effectiveness, organizational and safety aspects of new
treatments as shown in Table 2. The number of domains
mentioned varied between one and nine, but most respon-
dents mentioned information within three or four domains.
The most frequent combination of information needed was
within the domains on clinical effectiveness and economic
aspects alone (ﬁve respondents) or in combination with
organizational aspects (three respondents) or safety (three
respondents).
Table 3
The types of information considered by hospital and clinical managers
to  be the most relevant when making decisions about investing in new
treatments (based on Question 6).
Domain Number of
respondents
(N = 53)
Proportion
D1: Health problem 12 22.6%
D2: Content of treatment 1 1.9%
D3: Clinical effectiveness 38 71.7%
D4: Safety 20 37.7%
D5: Economics 39 73.6%
D6: Ethics 2 3.8%
D7: Organizational aspects 11 20.8%
D8: Social aspects 1 1.9%
D9: Legal aspects 1 1.9%
D10: Political and strategic aspects 10 18.9%
Table 2 also shows the answers to Question 5 about
additional information that should be part of the basis for
decision making. The number of domains mentioned var-
ied between zero and nine. As the table shows, information
within all domains are considered relevant by at least 50%
of the respondents.
Table 3 shows the types of information considered as
most relevant by the respondents (Question 6 in Box 1).
Of the 53 respondents, 50 identiﬁed some information as
being more relevant than other information. Only three
respondents said that all types of information were equally
important.
The most frequent combinations of information that
the respondents considered as most relevant were
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Box 2: Examples of political and strategic
aspects of new treatments mentioned by the
respondents.
Political aspects Strategic aspects
(No 2): “Political
decisions often
overrule everything
else. That we know
of.”
(No 23) “Political
aspects are growing
in Finland.”
(No. 3) “Research strategies.”
(No. 16) “Even if we do not like it,
political/strategic considerations are
very important because if one wants to
be a pioneer in the ﬁeld, we have to be
the ﬁrst to adopt a new technology.”
(No. 16) “Strategic aspects in order to
become an authority in Spain and
Europe.”
(No. 8) “Political aspects no. But
hospital strategic aspects are relevant.”
(No. 23) “Political no. But hospital has
strategy.”
(No 24) “In Finland politics affect only
on budget, but in our hospitals we have
our own strategy.”
(No. 34) “The hospital has its strategic
investment plan.”
(No. 38) “Relevant information is also if
a  technology is “proﬁle-building.”
(i) clinical and economic aspects (10 respondents) or (ii)
clinical, safety and economic aspects (9 respondents). As
the table shows, clinical effectiveness and economics were
considered as the most important information by more
than 70% of the respondents. Hereafter comes informa-
tion on safety, the patients’ health problem, organizational
aspects and political and strategic aspects.
Tables 2 and 3 show consistency in the answers to
Questions 4 and 6. The economic and clinical aspects of
new treatments are mentioned most and second most fre-
quently in both questions and the ﬁve most frequent types
of information are also the same in the two questions.
3.3. The importance of political and strategic aspects
Political and strategic aspects were identiﬁed as rel-
evant for hospital based HTA in the literature review
[17]. Political aspects refer for example to the alignment
between the decision to invest in a technology and the local
political climate or values. Strategic aspects refer for exam-
ple to the ﬁt between a given technology and the hospital’s
research strategy. After the identiﬁcation and coding of the
terms used by the respondents in the interviews, the terms
were divided in these two groups. The terms that were
coded into this tenth domain were subsequently divided
into political and strategic aspects (see Box 2 for verbatim
quotations from respondents). Most of the terms related
to the hospital’s own strategic research goals, competition
with other hospitals, proﬁle-building and investment. The
number of each respondent is presented in brackets.
3.4. The content of the economic aspects
The respondents’ perception of the type of information
they need regarding economics was also captured. Box 3
shows some examples of quotes from respondents who
Box 3: Examples of societal and hospital
perspective in the need for information on eco-
nomic aspects in Questions 4, 5 or 6 (see Box
1).
Societal
perspective
Hospital
perspective
Both societal and
hospital
perspective
(No 1): “Focus
should to a
greater extent be
on a wider
perspective
across health
care (e.g. general
practice,
hospital).”
(No. 18) “Cost-
effectiveness,
cost-QALY.
Whether the
technology will
help to reduce
length of stay,
use of human
resources, less
complications,
long term
effects.  . .”
(No. 24) “There’s
no use to get same
results spending
more money than
with previous
techniques. Budget
gives the frames
for what we are
able to invest in.”
(No 33): “The
services are
provided and new
technologies
purchased only in
case these are
ﬁnanced by the
EHIF (Estonian
Health Insurance
Fund) and listed in
the annual
contract.”
(No. 34) “There is
no way to
implement
technologies, which
are not covered by
the annual
contract.”
(No 35) “Cost of
treatment is
important as
cost-effectiveness
has to be favorable
in order the Health
Insurance will
approve the
treatment and add
it to the list of
reimbursed
services.”
(No. 36) “Direct
costs of technology
in comparison with
reimbursement
possibilities.”
(No. 37) “One time
investment,
multiple
consumables and
staff costs, staff
implications.”
(No. 38)
“Replacement or
new investment/
additional or
substitute,
supplier(s),
maintenance,
effects on staff
(need for less or for
more),
(No. 5) “Economy
of the department
as well as
socio-economy,
e.g. very expensive
medicine.
(No 9) “Very
important, for the
hospital as well as
for society
including private
businesses i.e.
return to work.”
(No. 16)
“Cost-effectiveness
is key. Maintenance
cost and fungibles
(e.g. batteries) are
important and may
be much  larger
than the initial
investment.”
(No. 27)
“Cost-effectiveness
and comparison are
important. Budget
is the biggest
determiner.”
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investment-costs
(once), running
costs/overheads,
additional costs (IT,
energy, heating,
room adaptation
etc.).  . ..”
(No 52)
“Acceptable costs
to the health care
system, with if
possible coverage
by the insurance
companies.”
(No 54) “Impact on
cost of care and
outpatient
treatment.”
(No 55) “Economic
aspects involved
setting up the
project, running the
project
(infrastructure and
equipment,
maintenance and
running costs,
personal and
training). A whole
chapter about
medical economic
analysis including
billing possibilities
and rate of
coverage is
included.
(No 56)
“Economical
aspects are
important but
sometimes, a new
technology should
be founded even if
leading to an
economical loss
(for example, until
it  is reimbursed or
until prices fall on
the market).”
(No. 57) “Economic
impact on hospital
given the DRG
system.”
mentioned the economic aspects as most relevant. These
quotes are divided in three groups:
• Economic information related to a societal perspective.
• Economic information related to a hospital perspective.
• Economic information related to both a societal and a
hospital perspective.
As shown in Box 3, it is not always clear whether
the respondents are having a societal or a more narrow
perspective of the economic aspects in mind. However,
some respondents clearly focused on the reimbursement
to the hospital and not the societal economic impact. The
examples also reveal that of the 39 respondents mention-
ing economics as one of the most relevant information (in
Question 6), about one third was  referring only to the eco-
nomic impact on the hospital by using terms like budget
impact, ﬁnancing, reimbursement and Diagnosis-Related
Groups (DRG). Only four respondents explicitly stated that
both a societal and a hospital perceptive on the economic
aspects were needed.
3.5. Variation between settings and types of managers
Respondents from university hospitals and those from
smaller hospitals varied somewhat in their answers to
Question 6 about the most important information between
respondents from university hospitals and smaller hospi-
tals. The major difference was that hospital managers from
university hospitals more frequently mentioned informa-
tion related to the clinical and economic aspects as the most
relevant information, whereas managers from smaller hos-
pitals more frequently mentioned information related to
the organizational and the political and strategic domain.
The differences between the answers from clinical and hos-
pital managers were smaller. Table 4 shows these results.
3.6. Differences between countries
Because of the small number of respondents, it was
difﬁcult to identify differences between countries. In the
content analysis, however, some types of information were
more often considered to be important in decision-making
(Question 6 in Box 1) in some countries, see Box 4.
4. Discussion
This interview study with 53 hospital managers from
nine European countries found that information about clin-
ical effectiveness and economic aspects were considered
the most relevant when deciding about investments in new
treatments. Hereafter comes information on safety, orga-
nizational aspects and the health problem of the patients.
About one in ﬁve respondents also considered infor-
mation on the political and strategic aspects as important
in decision making. When looking at the terms used by
the respondents, the results indicate that in particular the
relation between investment in new treatments and the
hospitals’ strategic goals (e.g. regarding research or com-
petition) are of importance. This has also been suggested
recently in other studies [21] and [22]. The political and
strategic information domain is not included in the HTA
Core Model, suggesting that the need for this kind of infor-
mation is speciﬁc for hospital based HTA and perhaps not
relevant for national HTA institutions and thus not typically
included in guidelines for national HTA.
Analysis of the terms used by the respondents also
shows that the economic focus of the hospital managers is
quite narrow. The respondents are often focused on budget
impact and reimbursement and less frequently on societal
cost–utility analysis. This has also been demonstrated in
other studies in [19,23].
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Table 4
The types of information considered by managers from university hospitals and smaller hospitals to be the most relevant when making decisions about
investing in new treatments (based on Question 6).
Domain Managers from university hospitals (N = 35) Managers from smaller hospitals (N = 18)
Number of respondents Proportion Number of respondents Proportion
D1: Health problem 8 23.5% 4 21.1%
D2:  Content of treatment 1 2.9% 0 0.0%
D3:  Clinical effectiveness 27 79.4% 11 57.9%
D4:  Safety 14 41.2% 7 36.8%
D5:  Economics 27 79.4% 12 63.2%
D6:  Ethics 3 8.8% 0 0.0%
D7:  Organizational aspects 6 17.6% 7 36.8%
D8:  Social aspects 1 2.9% 0 0.0%
D9:  Legal aspects 1 2.9% 0 0.0%
D10:  Political and strategic aspects 5 14.7% 5 26.3%
Box 4: Examples of answers from different
countries reflecting the importance of informa-
tion about the economic impact on the hospital.
Estonia:
- (No. 34) “It has to be sure that the technologies will
not create economic losses to the hospital and for
most investment decisions cost–recovery analysis
are sufﬁcient.”
- (No 33) “The services are provided and new tech-
nologies purchased only in case these are ﬁnanced
by the EHIF (Estonian Health Insurance Fund) and
listed in the annual contract.”
- (No 36) “In Estonia 99% of decisions to implement or
reject new technologies are not made at the hospital
level, but by the Estonia Health Insurance Fund.”
Switzerland:
- (No. 52) “Availability of the technology in the can-
ton in Switzerland or in Europe and the existence of
concurrence in this ﬁeld is important. The competi-
tion between public and private sector is obviously
interesting.”
- (No 55) “However, in Switzerland, outpatient treat-
ment is totally free and anybody can enter the
market, whereas there is some regulation in the pub-
lic sector of hospitals. This aspect should be taken
into account if present.”
Turkey:
• (No. 61) “Patient demand was the primary factor for
the decision making process.”
• (No. 63) “Patients’ demands mainly forced us for
the DaVinci robot. Patients preferred hospitals with
robots for prostatectomy. So we decided to buy one
to increase number of urologic cases.”
Our interview ﬁndings are generally consistent with the
results of a systematic literature review carried out prior
to the interview study [17]. The review also found a high
frequency of studies indicating that clinical and economic
aspects of new health technologies are of most importance
to hospital managers. The current interview study can be
seen as a validation of the results from the review.
A relatively small number of respondents are included
in this interview study, and that respondents were selected
by local (i.e. hospital), regional or national HTA institutions
involved in the AdHopHTA project. The respondents should
thus not be considered representative for all hospital man-
agers in Europe. Instead there is a risk that managers and
hospitals with an interest in HTA and evidence based deci-
sion making have a higher probability of being included
in the study. However, it should be noticed that the aim
of the study was  to do a qualitative study and to get
an understanding of hospital managers need for informa-
tion.
The strength of the method used is that personal inter-
view is more relevant when the subject and the questions
are complicated and when the speciﬁc wordings and terms
used by the respondents are of interest. Also the use of
local interviewers with a good understanding of the health
care system in the country may  have resulted in more valid
answers and fewer misunderstandings.
The weakness of this study is that different interview-
ers have carried out the interviews in different countries.
Even though a detailed interview instructions were pro-
duced (see online Appendix) and the interviewers were
trained in the use of the questionnaire and the reporting
template, there is still a risk that different understandings
of the questions and tasks by the interviewers have had
inﬂuence on the results from the interviews. The transla-
tion of the respondents answer into English may  also have
inﬂuenced the reporting of the results.
When considering the variation in the respondents’
answers it should also be considered that hospital man-
agers need for information may  also vary with the type
of health technology in question. To reduce this problem
the respondents were asked about their information needs
when deciding on investment in new treatments in order
to focus on the smaller group of new medical or surgi-
cal treatments. However, there is still a risk that variation
in the answers reﬂects that respondents were consider-
ing different types of health technologies when answering
the questions. Similar, some of the variation in the need
for information about economic aspects of new treatments
may  reﬂect differences in the local reimbursement systems
in the countries involved in the study.
In addition it is unknown to what extent the answers
from the hospital managers are reﬂecting the managers’
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true need for information – or rather the managers’ per-
ception of the socially, politically or scientiﬁcally correct
answer. This kind of social desirability bias may  have been
present [20]. For example hospital and clinical managers
may  not reveal the inﬂuence off third parties (e.g. local
politicians, pharmaceutical industry, patient lobbies etc.)
on the use of information in their decisions.
The results may  also simply reﬂect the medical educa-
tional background of the respondents. However, the ﬁrst
question about need for information (see Question 4 in Box
1) was an open question with no limitation on the answer.
The fact that the most frequent answer was related to the
economic domain probably reﬂects that the respondents
are hospital managers dealing with hospital costs and rev-
enues in their daily life.
If the results are considered valid and consistent with
other studies of the need for information by hospital man-
agers in Europe, then the implication for hospital based HTA
need to be considered. One implication could be that hospi-
tal based HTA approaches – e.g. mini-HTA [8] – should focus
on the clinical, economic, safety and organizational aspects
of new treatments. However, as the answers to Question 5
show (see Table 2) information about the other domains
can also be relevant to hospital managers and should not
be considered insigniﬁcant.
Another implication is that assessment of the economic
impact should focus on the consequences for the hospi-
tal and include budget impact and reimbursement issues.
Societal cost–utility analysis is not irrelevant but should be
combined with economic analyses with a narrower per-
spective.
In addition, the study ﬁndings also suggest that descrip-
tion of the strategic aspects for the hospital considering
investing in a new treatment should be included in hospi-
tal based HTA. This is quite different from the traditional
content of HTA, as described in e.g. the HTA Core Model
[14,15] and opens the door to new and strategic aspects of
decision making to be included in the hospital based HTA
report. More research is needed on this subject before the
practical implications for hospital based HTA is clear and
this subject will be included in a large scale survey of Euro-
pean hospital and clinical managers that is planned as the
next step in the AdHopHTA project.
5. Conclusions
The results from this interview study with 53 European
hospital managers show that their need for information
in decision making about new treatments deviate from
known accepted guidelines for production of HTA, as
described in e.g. the HTA Core Model. The clinical, eco-
nomic, safety and organizational aspects of new treatments
were considered the most relevant information for deci-
sion making. However, at the same time the results reveal
that information about other domains can also be of rele-
vance to hospital managers and should not be considered
insigniﬁcant. With regard to the economic aspects, hospi-
tal managers often have a quite narrow focus on budget
impact and reimbursement. In addition to the traditional
HTA domains hospital managers sometimes also need
information about the political and strategical aspects of
new treatments, in particular the relationship between the
new technology and the strategic goals of the hospital. This
shows the need to contextualize HTA information to the
hospital setting. If further studies are able to verify these
results, guidelines for hospital based HTA should be altered
to reﬂect the informational needs of hospital managers for
deciding about whether to invest in new treatments.
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